Centene Corp
CNC: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| q<@ | LOCK|y%> | LOCK|%&NXMBw |
Centene Earnings: Rising Medical Costs Constrain 2025 Outlook, but Growth Expected in 2026
After withdrawing 2025 guidance in early July due primarily to challenges in the individual exchange market, Centene turned in a second-quarter loss after its medical loss ratio ballooned to 93%, despite 18% growth in premium and service revenue. Guidance for 2025 now includes $1.75 of adjusted EPS.
